Study wrapper · #830
Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.
Editor's note
A small randomized controlled trial (60 women) testing low-dose tirzepatide added to metformin versus metformin alone in overweight/obese Chinese women with polycystic ovary syndrome (PCOS) — a directly tirzepatide-specific study extending the peptide into a reproductive-endocrine context beyond its diabetes and obesity base. Over 16 weeks the combination arm showed markedly greater weight loss (-10.4 vs -1.7 kg), larger reductions in BMI and visceral fat, and improvements in reproductive-endocrine parameters, with higher rates of menstrual-cycle recovery and pregnancy after switching back to metformin. The design is a genuine strength (randomized, prospective), but weigh it against real limits: it is small, open-label (no blinding, so expectation effects are possible), single-centre, short, and PCOS-specific to one population. The pregnancy-rate signal is intriguing but based on tiny numbers. This is a promising, well-scoped signal for tirzepatide in PCOS-related weight and metabolic outcomes, appropriately held as early rather than definitive.
Plain-language abstract
This randomized trial tested whether adding a low dose of tirzepatide to the common medication metformin helps overweight women with polycystic ovary syndrome (PCOS), a hormonal condition linked to weight gain, irregular periods, and difficulty conceiving. Sixty women were randomly assigned to take either metformin alone or metformin plus a weekly tirzepatide injection for 16 weeks. The combination group lost far more weight (about 10 kg versus under 2 kg), had bigger drops in BMI and in fat around the organs, and showed better hormone and metabolic measures. After the 16 weeks, everyone switched to metformin alone, and the group that had received tirzepatide had more women with restored menstrual cycles and higher pregnancy rates. The trial's random assignment is a strength, but it was small, conducted at one site, relatively short, and not blinded — meaning both patients and doctors knew who got which treatment, which can influence results. The pregnancy findings come from small numbers. So this is an encouraging early signal for tirzepatide in PCOS, not a settled conclusion.